Volume 14, Number 3—March 2008
Research
Mycobacterium xenopi Clinical Relevance and Determinants, the Netherlands
Jakko van Ingen*†
, Martin J. Boeree*, Wiel C.M. de Lange*, Wouter Hoefsloot*, Saar A. Bendien*, Cecile Magis-Escurra*, Richard Dekhuijzen*, and Dick van Soolingen†
, Martin J. Boeree*, Wiel C.M. de Lange*, Wouter Hoefsloot*, Saar A. Bendien*, Cecile Magis-Escurra*, Richard Dekhuijzen*, and Dick van Soolingen†Table 2
Baseline in vitro susceptibility of 47 primary isolates from 42 patients with nontuberculous mycobacterial infection, the Netherlands, January 1999 through March 2005
| Susceptibility | Drug, no. (%), MIC |
||
|---|---|---|---|
| Isoniazid | Rifampin | Ethambutol | |
| Susceptible | 9 (21), MIC 0.2 mg/L | 29 (69), MIC <1mg/L | 5 (12), MIC 5 mg/L |
| Intermediate | 32 (76), MIC 0.5–1.0 mg/L | 11 (26), MIC 10 mg/L | |
| Resistant | 1 (2), MIC >1 mg/L | 13 (31), MIC >1 mg/L | 26 (62), MIC >10 mg/L |
